# Telmisartan

Drug · id `cardio:telmisartan` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Micardis

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: High blood pressure; Coronary and vascular disease  

## In plain language

Telmisartan is an ARB (angiotensin II receptor blocker), a medicine taken by mouth. The US label read, for telmisartan tablets (a generic product), lists two uses: treating high blood pressure, and reducing the risk of heart attack (myocardial infarction), stroke or cardiovascular death in patients 55 or older at high risk who are unable to take ACE inhibitors. The label read is a generic product label; the brand names for this substance are recorded as aliases.

## Technical summary

RxNorm ingredient 73494; UNII U5SYW473RQ. UNII U5SYW473RQ is the UNII of the substance as the label names it. MeSH descriptor D000077333 is Telmisartan. Class: Angiotensin 2 Receptor Blocker (FDA established pharmacologic class, RxClass). The label read is the Ascend Laboratories, LLC label for telmisartan tablets, application ANDA205150, effective 2025-03-29 in openFDA; Drugs@FDA lists the application's sponsor as ADAPTIS. The brand label for Micardis (listed as discontinued in Drugs@FDA), other generic telmisartan labels and the combination labels were not used. This page records label indications and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Patients for whom the US label of telmisartan tablets lists an indication: hypertension, cardiovascular risk reduction in patients 55 or older at high risk who are unable to take ACE inhibitors

Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The risk reduction indication names patients 55 years of age or older at high risk who are unable to take ACE inhibitors; the hypertension indication does not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: 55 years or older for the risk reduction indication, as the passage read states; not stated for hypertension; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of telmisartan tablets, USP, in the Ascend Laboratories, LLC version dated 2025-03-29 in openFDA (a generic product), lists the medicine for the treatment of hypertension, to lower blood pressure; and for reduction of the risk of heart attack (myocardial infarction), stroke or cardiovascular death in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The risk reduction indication names patients 55 years of age or older at high risk who are unable to take ACE inhibitors; the hypertension indication does not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: 55 years or older for the risk reduction indication, as the passage read states; not stated for hypertension; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for telmisartan tablets, USP, Ascend Laboratories, LLC label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 29bddc43-2809-4e1f-ae35-2865e15e9bb6 (manufacturer Ascend Laboratories, LLC, application ANDA205150), returned on 2026-11-09. The label text is dated 2025-03-29 (effective\_time). Other openFDA records of telmisartan labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2229bddc43-2809-4e1f-ae35-2865e15e9bb6%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-09T13:26:57Z. Source state: Current. Version fingerprint: 13ec09d12943dd0899ef011d1e41530a3b174ce48e3dbf6df4fab4d2d936f9ee.
     How it applies: The label sentences that give the indications named in the statement, each quoted in the research quote table.
  2. Supports: openFDA drug label record for telmisartan tablets, USP, Ascend Laboratories, LLC label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 29bddc43-2809-4e1f-ae35-2865e15e9bb6 (manufacturer Ascend Laboratories, LLC, application ANDA205150), returned on 2026-11-09. The label text is dated 2025-03-29 (effective\_time). Other openFDA records of telmisartan labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2229bddc43-2809-4e1f-ae35-2865e15e9bb6%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[1\], 1.2 Cardiovascular Risk Reduction. Retrieved 2026-11-09T13:26:57Z. Source state: Current. Version fingerprint: 13ec09d12943dd0899ef011d1e41530a3b174ce48e3dbf6df4fab4d2d936f9ee.
     How it applies: The label sentences that give the indications named in the statement, each quoted in the research quote table.
  3. Background: openFDA drug label record for telmisartan tablets, USP, Ascend Laboratories, LLC label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 29bddc43-2809-4e1f-ae35-2865e15e9bb6 (manufacturer Ascend Laboratories, LLC, application ANDA205150), returned on 2026-11-09. The label text is dated 2025-03-29 (effective\_time). Other openFDA records of telmisartan labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2229bddc43-2809-4e1f-ae35-2865e15e9bb6%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:26:57Z. Source state: Current. Version fingerprint: 13ec09d12943dd0899ef011d1e41530a3b174ce48e3dbf6df4fab4d2d936f9ee.
     How it applies: Effective date of the label text read, 20250329.
  4. Background: openFDA Drugs@FDA record for application ANDA205150 (TELMISARTAN, sponsor ADAPTIS): product and sponsor (Regulator, edition The openFDA Drugs@FDA record for application ANDA205150, returned on 2026-11-09. It lists the sponsor and the products of the application; only the first product listing is quoted.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:%22ANDA205150%22&limit=1>
     Locator: results\[0\].products\[0\].brand\_name. Retrieved 2026-11-09T13:26:58Z. Source state: Current. Version fingerprint: b4e8cbf33dbae999da26c62354a47273feb6e44843edb33850370266ed19bb56.
     How it applies: Drugs@FDA product listing for application ANDA205150, which confirms the product the label belongs to.

## Connected pages

- Telmisartan is an ARB (FDA established pharmacologic class in RxClass): Angiotensin receptor blockers (ARBs) (`cardio:angiotensin-receptor-blockers-arbs`)
- FDA label lists hypertension as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-telmisartan-label-indications` and its context]
- FDA label lists reduction of the risk of myocardial infarction, stroke or cardiovascular death in people 55 or older at high risk who are unable to take ACE inhibitors as an indication: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`) [a claim, not a settled fact; see claim `cardio:claim-fda-telmisartan-label-indications` and its context]
- FDA label lists reduction of the risk of myocardial infarction, stroke or cardiovascular death in people 55 or older at high risk who are unable to take ACE inhibitors as an indication: Stroke (`core:stroke`) [a claim, not a settled fact; see claim `cardio:claim-fda-telmisartan-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 4 registry products
- 11 registry trials

## Provenance

Content hash: a760ec635099a0180b5495d252d9e115c4efddd62fab90e479441b00110affec
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
